Wall Street is having a rough week in Washington, D.C.
Just one day after Wells Fargo’s (WFC) CEO John Stumpf was raked over the coals by the Senate Committee on Oversight on Tuesday, Mylan’s (MYL) CEO Heather Bresch appeared in the House of Representatives to testify on the rising prices of EpiPens.
Both Democrat and Republican representatives on the House Oversight and Government Reform Committee pressed Bresch and Doug Thockmorton, a representative from the Food and Drug Administration, on the cost of EpiPen and it’s lack of competitors in the pharmaceutical industry.
